COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes-Reference-Cited by-同舟云学术

COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes

Published:2022-09-21 Issue:3 Volume:35 Page:
ISSN:0893-8512
Container-title:Clinical Microbiology Reviews
language:en
Short-container-title:Clin Microbiol Rev

Author:

Focosi Daniele¹^ORCID,Franchini Massimo²,Pirofski Liise-anne³,Burnouf Thierry⁴⁵,Paneth Nigel⁶⁷,Joyner Michael J.⁸,Casadevall Arturo⁹^ORCID

Affiliation:

1. North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy

2. Division of Transfusion Medicine, Carlo Poma Hospital, Mantua, Italy

3. Division of Infectious Diseases, Albert Einstein College of Medicine and Montefiore Medical Center, New York, New York, USA

4. Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan

5. International Ph.D. Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan

6. Department of Epidemiology & Biostatistics and Pediatrics & Human Development, College of Human Medicine, Michigan State University, East Lansing, Michigan, USA

7. Department of Pediatrics & Human Development, College of Human Medicine, Michigan State University, East Lansing, Michigan, USA

8. Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA

9. Department of Medicine, Johns Hopkins School of Public Health and School of Medicine, Baltimore, Maryland, USA

Abstract

Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is available as soon as there are survivors. The COVID-19 pandemic represented the first large-scale opportunity to shed light on the mechanisms of action, safety, and efficacy of CP using modern evidence-based medicine approaches. Studies ranging from observational case series to randomized controlled trials (RCTs) have reported highly variable efficacy results for COVID-19 CP (CCP), resulting in uncertainty.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Microbiology (medical),Public Health, Environmental and Occupational Health,General Immunology and Microbiology,Epidemiology

Link

https://journals.asm.org/doi/pdf/10.1128/cmr.00200-21

Reference152 articles.

1. The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19

2. The convalescent sera option for containing COVID-19

3. Hark back: Passive immunotherapy for influenza and other serious infections

4. Effectiveness of convalescent plasma therapy in severe COVID-19 patients

5. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of convalescent plasma and hyperimmune immunoglobulins in the COVID-19 pandemic, including implications for future preparedness;Frontiers in Immunology;2024-09-09

2. Unlocking the therapeutic potential of edible mushrooms: Ganoderma and their secondary metabolites as novel antiviral agents for combating COVID-19;New Zealand Journal of Botany;2024-08-08

3. An in‐depth analysis of COVID‐19 treatment: Present situation and prospects;Archiv der Pharmazie;2024-08-06

4. Association between COVID-19 convalescent plasma antibody levels and COVID-19 outcomes stratified by clinical status at presentation;BMC Infectious Diseases;2024-06-26

5. COVID-19 therapeutics;Clinical Microbiology Reviews;2024-06-13